文献类型：期刊文章

作　　者：胡晓庆[1] 张聿达[2] 陈阳倩[2] 向思琦[3] 言欢[2] 秦浩越[2] 黄哲[2] 张星[2] 马宏志[4] 张琳[5] 曾亮[6] 张永昌[6] 杨农[6]

HU Xiaoqing;ZHANG Yuda;CHEN Yangqian;XIANG Siqi;YAN Huan;QIN Haoyue;HUANG Zhe;ZHANG Xing;MA Hongzhi;ZHANG Lin;ZENG Liang;ZHANG Yongchang;YANG Nong(Department of Epidemiology and Health Statistics,Xiangya School of Public Health,Central South University,Changsha,410078,Hunan,China;Department of Medical Oncology,Graduate Collaborative Training Base of Hunan Cancer Hospital,Hengyang Medical School,University of South China,Hengyang,421001,Hunan,China;Department of Biochemistry and Immunology,College of Medical Science,Jishou University,Jishou,416000,Hunan,China;Department of Head and Neck Radiotherapy II,Lung Cancer and Gastrointesti-nal Unit,Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha,410013,Hunan,China;Department of Thoracic Radiotherapy I,Lung Cancer and Gastrointesti-nal Unit,Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha,410013,Hunan,China;Department of Medical Oncology,Lung Cancer and Gastrointesti-nal Unit,Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha,410013,Hunan,China)

机构地区：[1]中南大学湘雅公共卫生学院流行病与卫生统计系,湖南长沙410078 [2]南华大学衡阳医学院湖南省肿瘤医院研究生协作培养基地,湖南衡阳421001 [3]吉首大学医学院生物化学与免疫学系医学研究中心,湖南吉首416000 [4]湖南省肿瘤医院头颈放疗二科,湖南长沙410013 [5]湖南省肿瘤医院胸部放疗一科,湖南长沙410013 [6]湖南省肿瘤医院肺胃肠内科,湖南长沙410013

出　　处：《肿瘤药学》

年　　份：2023

卷　　号：13

期　　号：6

起止页码：702-708

语　　种：中文

收录情况：EMBASE、JST、UPD、ZGKJHX、普通刊

摘　　要：肺癌是全球最常见的恶性肿瘤之一,KRAS是肺癌发生基因突变的重要位点。由于KRAS突变亚型中常缺乏药理学药物靶向的口袋,KRAS突变位点一直被认为是“不可成药”的靶点。本文主要概括了KRAS突变型肺癌的作用机制和KRAS成药所面临的困难,并对KRAS突变的治疗策略和耐药机制的最新进展进行阐述。

关 键 词：KRAS突变  非小细胞肺癌 免疫疗法 靶向治疗 Sotorasib  Adagrasib  

分 类 号：R734.2]